Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Estrogen Receptor β as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps

Estrogen Receptor β as a Prognostic Marker of Tumor Progression in Colorectal Cancer with... The incidence of colorectal cancer (CRC) is lower in women than in men, and sex steroids can be considered contributing factors because oral contraception usage and estrogen replacement therapy are associated with decreased risk. Conversely, colorectal polyp development in familial adenomatous polyposis (FAP) begins during puberty. The objectives were to evaluate the relationship between the expression of these hormone receptors and adenoma-carcinoma progression, CRC stage and overall survival. We studied 120 A.C. Camargo Cancer Center patients diagnosed with either FAP-associated or spontaneous adenomatous polyps or CRC to determine the immunohistochemical expression levels of estrogen receptor (ER)-α, ER-β and the progesterone and androgen receptors (480 analyses). The ER-β expression levels differed between the groups: the group with FAP polyps had lower ER-β expression than that of the sporadic polyp group. With transformation of the sporadic polyps to cancer, there was a considerable decrease in ER-β expression (from 90% with strong expression to 80% with absent or weak expression) (p < 0.001). The ER-β expression was lower in T3/T4 tumors than in T1/T2 tumors (p = 0.015). The 5-year overall survival of CRC patients positively expressing ER-β exceeded that of patients without detectable expression levels (74.8% vs. 44.3%, respectively; p = 0.035). There was no significant expression of the androgen or progesterone receptor or ER-α among the groups. Differences in ER-β expression represent a potential mechanism through which estrogen might alter the susceptibility to colon cancer, thereby confirming the possibility of a protective role of estrogen against colorectal carcinogenesis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pathology & Oncology Research Springer Journals

Estrogen Receptor β as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps

Download PDF
8 pages

Loading next page...
 
/lp/springer_journal/estrogen-receptor-as-a-prognostic-marker-of-tumor-progression-in-0tFrn07x0g
Publisher
Springer Journals
Copyright
Copyright © 2017 by Arányi Lajos Foundation
Subject
Biomedicine; Cancer Research; Oncology; Pathology; Immunology; Biomedicine, general
ISSN
1219-4956
eISSN
1532-2807
DOI
10.1007/s12253-017-0268-5
pmid
28681123
Publisher site
See Article on Publisher Site

Abstract

The incidence of colorectal cancer (CRC) is lower in women than in men, and sex steroids can be considered contributing factors because oral contraception usage and estrogen replacement therapy are associated with decreased risk. Conversely, colorectal polyp development in familial adenomatous polyposis (FAP) begins during puberty. The objectives were to evaluate the relationship between the expression of these hormone receptors and adenoma-carcinoma progression, CRC stage and overall survival. We studied 120 A.C. Camargo Cancer Center patients diagnosed with either FAP-associated or spontaneous adenomatous polyps or CRC to determine the immunohistochemical expression levels of estrogen receptor (ER)-α, ER-β and the progesterone and androgen receptors (480 analyses). The ER-β expression levels differed between the groups: the group with FAP polyps had lower ER-β expression than that of the sporadic polyp group. With transformation of the sporadic polyps to cancer, there was a considerable decrease in ER-β expression (from 90% with strong expression to 80% with absent or weak expression) (p < 0.001). The ER-β expression was lower in T3/T4 tumors than in T1/T2 tumors (p = 0.015). The 5-year overall survival of CRC patients positively expressing ER-β exceeded that of patients without detectable expression levels (74.8% vs. 44.3%, respectively; p = 0.035). There was no significant expression of the androgen or progesterone receptor or ER-α among the groups. Differences in ER-β expression represent a potential mechanism through which estrogen might alter the susceptibility to colon cancer, thereby confirming the possibility of a protective role of estrogen against colorectal carcinogenesis.

Journal

Pathology & Oncology Research – Springer Journals

Published: Jul 5, 2017

References

  • Global cancer statistics
    Jemal, A; Bray, F; Center, MM; Ferlay, J; Ward, E; Forman, D
  • Combined molecular and clinical approaches for the identification of families with familial adenomatous polyposis coli
    Gebert, JF; Dupon, C; Kadmon, M; Hahn, M; Herfarth, C; Knebel, DM; Schackert, HK
  • Biology of the adenomatous polyposis coli tumor suppressor
    Goss, KH; Groden, J
  • Guidelines for the clinical management of familial adenomatous polyposis (FAP)
    Vasen, HF; Möslein, G; Alonso, A; Aretz, S; Bernstein, I; Bertario, L; Blanco, I; Bülow, S; Burn, J; Capella, G; Colas, C; Engel, C; Frayling, I; Friedl, W; Hes, FJ; Hodgson, S; Järvinen, H; Mecklin, JP; Møller, P; Myrhøi, T; Nagengast, FM; Parc, Y; Phillips, R; Clark, SK; Leon, MP; Renkonen-Sinisalo, L; Sampson, JR; Stormorken, A; Tejpar, S; Thomas, HJ; Wijnen, J
  • Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature
    Nieuwenhuis, MH; Vasen, HF
  • Oestrogen and the colon: potential mechanisms for cancer prevention
    Kennelly, R; Kavanagh, DO; Hogan, AM; Winter, DC
  • Oral contraceptives and polyp regression in familial adenomatous polyposis
    Giardiello, FM; Hylind, LM; Trimbath, JD; Hamilton, SR; Romans, KE; Cruz-Correa, M; Corretti, MC; Offerhaus, JA; Yang, VW
  • Estrogen plus progestin and colorectal cancer in postmenopausal women
    Chlebowski, RT; Wactawski-Wende, J; Ritenbaugh, C; Hubbell, FA; Ascensao, J; Rodabough, RJ; Rosenberg, CA; Taylor, VM; Harris, R; Chen, C; Adams-Campbell, LL; White, E; Investigators, W's HI
  • Estrogen plus progestin and colorectal cancer incidence and mortality
    Simon, MS; Chlebowski, RT; Wactawski-Wende, J; Johnson, KC; Muskovitz, A; Kato, I; Young, A; Hubbell, FA; Prentice, RL
  • Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial
    Anderson, GL; Limacher, M; Assaf, AR; Bassford, T; Beresford, SA; Black, H; Bonds, D; Brunner, R; Brzyski, R; Caan, B; Chlebowski, R; Curb, D; Gass, M; Hays, J; Heiss, G; Hendrix, S; Howard, BV; Hsia, J; Hubbell, A; Jackson, R; Johnson, KC; Judd, H; Kotchen, JM; Kuller, L; LaCroix, AZ; Lane, D; Langer, RD; Lasser, N; Lewis, CE; Manson, J; Margolis, K; Ockene, J; O’Sullivan, MJ; Phillips, L; Prentice, RL; Ritenbaugh, C; Robbins, J; Rossouw, JE; Sarto, G; Stefanick, ML
  • Use of hormone replacement therapy and the risk of colorectal cancer
    Rennert, G; Rennert, HS; Pinchev, M; Lavie, O; Gruber, SB
  • Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis
    Green, J; Czanner, G; Reeves, G; Watson, J; Wise, L; Roddam, A; Beral, V
  • The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer
    Lin, KJ; Cheung, WY; Lai, JY; Giovannucci, EL
  • Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis
    Grodstein, F; Newcomb, PA; Stampfer, MJ
  • Ligand-dependent interaction between estrogen receptor alpha and adenomatous polyposis coli
    Kouzmenko, AP; Takeyama, K; Kawasaki, Y; Akiyama, T; Kato, S
  • Oestrogen receptors in colorectal carcinoma
    Dawson, PM; Shousha, S; Blair, SD; Carter, GD; Jones, J; Alaghband-Zadeh, J; Theodorou, NA
  • Oestrogen and progesterone receptors in colorectal cancer and human colonic cancer cell lines
    Hendrickse, CW; Jones, CE; Donovan, IA; Neoptolemos, JP; Baker, PR
  • Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa. Preliminary results
    Leo, A; Messa, C; Russo, F; Misciagna, G; Guerra, V; Taveri, R; Leo, S
  • Status of sex steroid hormone receptors in large bowel cancer
    Meggouh, F; Lointier, P; Pezet, D; Saez, S
  • Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer
    Slattery, ML; Sweeney, C; Murtaugh, M; Ma, KN; Caan, BJ; Potter, JD; Wolff, R
  • Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer
    Slattery, ML; Sweeney, C; Murtaugh, M; Ma, KN; Wolff, RK; Potter, JD; Caan, BJ; Samowitz, W
  • Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer
    Mostafaie, N; Kállay, E; Sauerzapf, E; Bonner, E; Kriwanek, S; Cross, HS; Huber, KR; Krugluger, W
  • HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing
    Rüschoff, J; Dietel, M; Baretton, G; Arbogast, S; Walch, A; Monges, G; Chenard, MP; Penault-Llorca, F; Nagelmeier, I; Schlake, W; Höfler, H; Kreipe, HH
  • Selective loss of estrogen receptor beta in malignant human colon
    Foley, EF; Jazaeri, AA; Shupnik, MA; Jazaeri, O; Rice, LW
  • Estrogen receptors α and β are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of min/+ mice
    Cho, NL; Javid, SH; Carothers, AM; Redston, M; Bertagnolli, MM
  • American joint committee on cancer staging manual
    Edge, SB; Byrd, DR; Compton, CC; Fritz, AG; Greene, FL; Trotti, A
  • Loss of expression of oestrogen receptor beta in colon cancer and its association with dukes’ staging
    Jassam, N; Bell, SM; Speirs, V; Quirke, P
  • Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation
    Konstantinopoulos, PA; Kominea, A; Vandoros, G; Sykiotis, GP; Andricopoulos, P; Varakis, I; Sotiropoulou-Bonikou, G; Papavassiliou, AG
  • New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer
    Jordan, VC
  • Function of nuclear sex hormone receptors in gene regulation
    Kato, S; Sato, T; Watanabe, T; Takemasa, S; Masuhiro, Y; Ohtake, F; Matsumoto, T
  • Modulation of oestrogen receptor signalling by association with the activated dioxin receptor
    Ohtake, F; Takeyama, K; Matsumoto, T; Kitagawa, H; Yamamoto, Y; Nohara, K; Tohyama, C; Krust, A; Mimura, J; Chambon, P; Yanagisawa, J; Fujii-Kuriyama, Y; Kato, S
  • Transcription in four dimensions: nuclear receptor-directed initiation of gene expression
    Métivier, R; Reid, G; Gannon, F
  • Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes
    Björnström, L; Sjöberg, M
  • Membrane-initiated actions of estrogens in neuroendocrinology: emerging principles
    Vasudevan, N; Pfaff, DW
  • Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis
    Nanda, K; Bastian, LA; Hasselblad, V; Simel, DL
  • Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer
    Slattery, ML; Potter, JD; Curtin, K; Edwards, S; Ma, KN; Anderson, K; Schaffer, D; Samowitz, WS